+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acute Myeloid Leukemia (AML) KOL Interview - US, South

  • PDF Icon


  • 16 Pages
  • March 2024
  • Region: United States
  • Citeline
  • ID: 5642900
An interview with a US-based key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Idhifa, Tibsovo, magrolimab, quizartinib, crenolanib, gilteritinib, and uproleselan.